

Leishmania IgG/IgM Rapid Test Strip Package Insert

Cat: ILE-421

Specimens: Whole Blood/Serum/Plasma

Version: 02

Effective Date: 2024-07

For professional *in vitro* diagnostic use only.

INTENDED USE

The Leishmania IgG/IgM Rapid Test is a lateral flow immunoassay for the qualitative detection of antibodies including IgG and IgM to the RK-39 of the subspecies of the *Leishmania donovani* (*L. donovani*), the *Visceral leishmaniasis* causative protozoans in human serum or plasma. This test is intended to be used as a screening test and as an aid in the diagnosis of the disease of *Visceral leishmaniasis*. Any reactive specimen with the Leishmania IgG/IgM Rapid Test must be confirmed with alternative testing method(s).

SUMMARY

Visceral leishmaniasis, or Kala-azar, is a disseminated infection caused by several subspecies of the *L. donovani*. The disease is estimated by the World Health Organization (WHO) to affect approximately 12 million people in 88 countries¹. It is transmitted to humans by bites of the *Phlebotomus* sandflies, which acquire infection from feeding on infected animals. Though it is a disease for poor countries, in Southern Europe, it has become the leading opportunistic infection in AIDS patients²⁻³.

Identification of *L. donovani* organism from the blood, bone marrow, liver, lymph nodes or the spleen provides a definite means of diagnosis. However, these test methods are limited by the sampling method and the special instrument requirement. Serological detection of anti-*L. donovani* Ab is found to be an excellent marker for the infection of *Visceral leishmaniasis*. Tests used in clinic include: ELISA, fluorescent antibody and direct agglutination tests⁴⁻⁵. Recently, utilization of *L. donovani* specific protein in the test has improved the sensitivity and specificity dramatically⁶⁻⁷.

The Leishmania IgG/IgM Rapid Test is a recombinant protein based serological test, which detects antibodies including IgG, IgM and IgA to the *L. donovani*. This test provides a reliable result within 10 minutes without any instrumentation requirements.

PRINCIPLE

The Leishmania IgG/IgM Rapid Test is a lateral flow chromatographic immunoassay. The test cassette consists of: 1) a burgundy colored conjugate pad containing recombinant *L. donovani* specific antigen RK-39 conjugated with colloid gold (Leishmania conjugates), 2) a nitrocellulose membrane strip containing a test band (T band) and a control band (C band). The T band is pre-coated with recombinant antigen RK-39 and the C band is pre-coated with chicken anti-protein A. When an adequate volume of test specimen is dispensed onto the sample pad of the test strip, the specimen migrates by capillary action across the strip. Anti-*L. donovani* Ab if present in the specimen will bind to the RK-39 antigen conjugates. The immunocomplex is then captured on the membrane by the pre-coated recombinant antigen RK-39, forming a burgundy colored T band, indicating a *L. donovani* Ab positive test result.

Absence of the T band suggests a negative result. The test contains an internal control (C band) which should exhibit a burgundy colored band of the immunocomplex of antibody- chicken anti-protein A -gold conjugate regardless of the color development on the C band. Otherwise, the test result is invalid and the specimen must be retested with another strip.

KIT COMPONENTS

Individually packed test strips	Each strip contains a strip with colored conjugates and reactive reagents pre-spread at the corresponding regions
Droppers	For adding specimens use
Buffer	Phosphate buffered saline and preservative
Package insert	For operation instruction

PRECAUTIONS

- For professional *in vitro* diagnostic use only. Do not use after expiration date.
- Wear protective clothing such as laboratory coats, disposable gloves and eye protection when specimens are being tested.
- Do not eat, drink or smoke in the area where the specimens or kits are handled.
- Handle all specimens as if they contain infectious agents. Observe established precautions against microbiological hazards throughout testing and follow the standard procedures for proper disposal of specimens.
- Humidity and temperature can adversely affect results.

STORAGE AND STABILITY

Store as packaged in the sealed pouch either at room temperature or refrigerated (2-30°C). The test strip is stable through the expiration date printed on the sealed pouch. The test strip must remain in the sealed pouch until use. **DO NOT FREEZE**. Do not use beyond the expiration date.

SPECIMEN COLLECTION AND PREPARATION

- The Leishmania IgG/IgM Rapid Test strip (Whole Blood/Serum/Plasma) can be performed using whole blood (from venipuncture or fingerstick), serum or plasma.
- To collect Fingerstick Whole Blood specimens:
Wash the patient's hand then allow to dry. Massage the hand without touching the puncture. Puncture the skin with a sterile lancet. Wipe away the first sign of blood. Gently rub the hand from wrist to palm to finger to form a rounded drop of blood over the puncture site. Add the Fingerstick Whole Blood specimen to the test strip by using a capillary tube or hanging drops.
- Separate serum or plasma from blood as soon as possible to avoid hemolysis. Use only clear, non-hemolyzed specimens.
- Testing should be performed immediately after specimen collection. Do not leave the specimens at room temperature for prolonged periods. Serum and plasma specimens may be stored at 2-8°C for up to 3 days. For long-term storage, specimens should be kept below -20°C. Whole blood collected by venipuncture should be stored at 2-8°C if the test is to be run within 2 days of collection. Do not freeze whole blood specimens. Whole blood collected by fingerstick should be tested immediately.
- Bring specimens to room temperature prior to testing. Frozen specimens must be completely thawed and mixed well prior to testing. Specimens should not be frozen and thawed repeatedly.
- If specimens are to be shipped, they should be packed in compliance with local regulations covering the transportation of etiologic agents.

MATERIALS

Materials Provided

- Test strips
- Buffer
- Droppers
- Package insert

Materials Required But Not Provided

- Specimen collection containers
- Centrifuge
- Lancets (for fingerstick whole blood only)
- Timer
- Heparinized capillary tubes and dispensing bulb (for fingerstick whole blood only)

DIRECTIONS FOR USE

- Bring the pouch to room temperature before opening it. Remove the test device from the sealed pouch and use it as soon as possible.
- Place the test strip on a clean and level surface.
Hold the dropper vertically and transfer 2 drops of sample (or approximately 50 µl) to the sample pad of the test strip, then add 1 drop of buffer (or approximately 40 µl) and start the timer.
- Wait for the red line(s) to appear. The result should be read at 15 minutes. Do not interpret the result after 30 minutes.

INTERPRETATION OF RESULTS

POSITIVE RESULT:



IgG Positive:* The colored line in the control line region (C) appears and a colored line appears in test line region 1 (T1). The result is positive for Leishmania specific-IgG antibodies.



IgM Positive:* The colored line in the control line region (C) appears and a colored line appears in test line region 2 (T2). The result is positive for Leishmania specific-IgM.



IgG and IgM Positive:* The colored line in the control line region (C) appears and two colored lines should appear in test line regions 1 and 2 (T1 and T2). The color intensities of the lines do not have to match. The result is positive for IgG & IgM antibodies.


***NOTE:** The intensity of the color in the test line region(s) (T1 and/or T2) will vary depending on the concentration of Leishmania antibodies in the specimen. Therefore, any shade of color in the test line region(s) (T1 and/or T2) should be considered positive.

NEGATIVE RESULT:



The colored line in the control line region (C) appears. No line appears in test line regions 1 or 2 (T1 or T2).

INVALID RESULT:



Control line (C) fails to appear. Insufficient buffer volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the procedure with a new test strip. If the problem persists, discontinue using the test kit immediately and contact your local distributor.

QUALITY CONTROL

Using individual Leishmania IgG/IgM Rapid Test strips as described in the Assay Procedure above, run 1 Positive Control and 1 Negative Control (provided upon request) under the following circumstances to monitor test performance:

- A new operator uses the kit, prior to performing testing of specimens.
- A new test kit is used.
- A new shipment of kits is used.
- The temperature used during storage of the kit falls outside of 2°C-30°C.
- The temperature of the test area falls outside of 15°C-30°C.

LIMITATIONS OF THE TEST

- The Assay Procedure and the Test Result Interpretation must be followed closely when testing the presence of antibodies to the *L. donovani* in serum or plasma from individual subjects. Failure to follow the procedure may give inaccurate results.
- The Leishmania Ab Combo Rapid Test is limited to the qualitative detection of antibodies to *L. donovani* in human serum or plasma. The intensity of the test band does not linearly correlate with the antibody titer in the specimen.
- A negative result for an individual subject indicates absence of detectable anti-*L. donovani* antibodies. However, a negative test result does not preclude the possibility of exposure to *Visceral leishmaniasis* causative species of the *L. donovani*.
- A negative result can occur if the quantity of the *L. donovani* antibodies present in the specimen is below the detection limits of the assay, or the antibodies that are detected are not present during the stage of disease in which a sample is collected.
- Some specimens containing unusually high titer of heterophile antibodies or rheumatoid factor may affect expected results.
- The results obtained with this test should only be interpreted in conjunction with other diagnostic procedures and clinical findings.

EXPECTED VALUES

The Leishmania IgG/IgM Rapid Test has been compared with a leading commercial EIA test, demonstrating an overall accuracy of 98.9%.

PERFORMANCE CHARACTERISTICS

Clinical Performance

A total of 267 patient samples from susceptible subjects were tested by the Leishmania IgG/IgM Rapid Test and by a commercial *L. donovani* IgG/IgM ELISA kit. Comparison for all subjects is shown in the following table.

EIA	Leishmania IgG/IgM Rapid Test		
	Positive	Negative	Total
Positive	52	2	54
Negative	1	212	213
Total	53	214	267

Relative Sensitivity: 96.3 %, Relative Specificity: 99.5%, Overall Agreement: 98.9%

PRECISION

Intra Assay

Within-run precision has been determined by using 10 replicates of three specimens containing negative, low positive and high positive samples. The negative and positive values were correctly identified >99% of the time.

Inter Assay

Between-run precision has been determined by using the three specimens of negative, low positive and high positive of 10 independent assays and with three different lots of the Leishmania IgG/IgM Rapid Test. The negative and positive values were correctly identified >99% of the time.

BIBLIOGRAPHY

1. WHO. Control of the Leishmaniasis. World Health Organization. Technical Report Series 1990. No. 793.
2. Rosenthal E, Marty P. Visceral leishmaniasis. *Rev Prat.* 2004;54(20):2211-6.
3. Molina R, Gradoni L, Alvar J. HIV and the transmission of Leishmania. *Ann Trop Med Parasitol.* 2003 ;97 Suppl 1:29-45.
4. Allain DS, Kagan IG. A direct agglutination test for leishmaniasis. *Am J Trop Med Hyg.* 1975 ;24(2):232-6.
5. Badaro R, Reed SG, Carvalho EM. Immunofluorescent antibody test in American visceral leishmaniasis: sensitivity and specificity of different morphological Am J Trop Med Hyg. 1983;32(3):480-4.
6. Maalej IA, Chenik M, Louzir H, Ben Salah A, et, al. Comparative evaluation of ELISAs based on ten recombinant or purified Leishmania antigens for the serodiagnosis of Mediterranean visceral leishmaniasis. *Am J Trop Med Hyg.* 2003 68(3):312-20.
7. Burns JM Jr, Shreffler WG, Benson DR, Ghalib HW, Badaro R, Reed SG. Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis. *Proc Natl Acad Sci U S A.* 1993 Jan 15;90(2):775-9.